Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024

Data will demonstrate ability of the assay to predict recurrence in patients treated for head & neck cancer Adela’s Chief Scientific Officer to chair Plenary Session FOSTER CITY, Calif., March 19, 2024 /PRNewswire/ — Adela, Inc., an innovator in blood testing for minimal residual disease…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks